Anabela Pinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anabela Pinto has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Mamede de Carvalho
University of Lisbon
20 shared publications - Susana Pinto
Institute of Physiology, Instituto de Medicina Molecular João Lobo Antunes, Centro de Estudos Egas Moniz, Faculdade de Medicina Universidade de Lisboa Lisbon Portugal
16 shared publications Teresinha Evangelista
Neuroscience Department, Hospital de Santa Maria-Centro Hospitalar Lisboa Norte, Lisbon
9 shared publications- Ana Londral
Comprehensive Health Research Centre, Lisbon, Portugal
3 shared publications - Isabel Conceição
ULS Santa Maria, CAML, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
3 shared publications - José Pedro Lopes De Almeida
Department of Physical Medicine and Rehabilitation, University of Lisbon Medical School, Santa Maria Hospital, Lisbon, Portugal
3 shared publications
Latest Publications
- 25 March 2015
- Published by Wiley in Muscle & Nerve
- Vol. 52 (6) , 933-941
Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages
Introduction: In this study we performed a longitudinal investigation to assess the impact of early introduction of assistive communication devices (ACDs) on quality of life (QoL) in amyotrophic lateral sclerosis (ALS) patients and their caregivers. Methods: Patients were followed for 7–10 months (3 evaluation periods). Bulbar‐onset ALS patients (N = 27) and paired caregivers (N = 17) were included. Fifteen randomly selected patients received early support in ACD use. Patients were assessed using the ALS Functional Rating Scale—revised (ALSFRS‐R), the McGill QoL (MQoL), the Communication Effectiveness Index (CETI), and performance in writing; and caregivers were assessed with the MQoL and World Health Organization Quality of Life questionnaire (WHOQOL‐BREF). Results: Patients with early support had higher MQoL Psychological and MQoL Existential well‐being domains; caregivers had higher MQoL Support domain and their MQoL Psychological domain positively associated with patient CETI. Most patients could communicate using a touchscreen keyboard to write, even when handwriting and speech were not possible. Conclusion: Early intervention with an ACD seems to have a positive impact on QoL and gives patients the opportunity to improve skills for communication in later disease stages. Muscle Nerve 52: 933–941, 2015
- 25 March 2015
- Published by Wiley in Muscle & Nerve
- Vol. 52 (6) , 933-941
Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages
Introduction: In this study we performed a longitudinal investigation to assess the impact of early introduction of assistive communication devices (ACDs) on quality of life (QoL) in amyotrophic lateral sclerosis (ALS) patients and their caregivers. Methods: Patients were followed for 7–10 months (3 evaluation periods). Bulbar‐onset ALS patients (N = 27) and paired caregivers (N = 17) were included. Fifteen randomly selected patients received early support in ACD use. Patients were assessed using the ALS Functional Rating Scale—revised (ALSFRS‐R), the McGill QoL (MQoL), the Communication Effectiveness Index (CETI), and performance in writing; and caregivers were assessed with the MQoL and World Health Organization Quality of Life questionnaire (WHOQOL‐BREF). Results: Patients with early support had higher MQoL Psychological and MQoL Existential well‐being domains; caregivers had higher MQoL Support domain and their MQoL Psychological domain positively associated with patient CETI. Most patients could communicate using a touchscreen keyboard to write, even when handwriting and speech were not possible. Conclusion: Early intervention with an ACD seems to have a positive impact on QoL and gives patients the opportunity to improve skills for communication in later disease stages. Muscle Nerve 52: 933–941, 2015
- Open Access
- 31 July 2013
- Published by Taylor & Francis in Pulmonology
- Vol. 19 (4) , 184-185
Mechanically Assisted Invasive Ventilation for ALS patients: Is it the Ultimate Strategy To Improve Survival?
- 31 July 2013
- Published by Taylor & Francis in Pulmonology
- Vol. 19 (4) , 184-185
Open AccessMechanically Assisted Invasive Ventilation for ALS patients: Is it the Ultimate Strategy To Improve Survival?
- Open Access
- 30 July 2013
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 19 (4) , 184-185
Mechanically Assisted Invasive Ventilation for ALS patients: Is it the Ultimate Strategy To Improve Survival?
- 30 July 2013
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 19 (4) , 184-185
Open AccessMechanically Assisted Invasive Ventilation for ALS patients: Is it the Ultimate Strategy To Improve Survival?
- 19 July 2013
- Published by Wiley in Muscle & Nerve
- Vol. 49 (4) , 545-550
Vascular endothelial growth factor and amyotrophic lateral sclerosis: The interplay with exercise and noninvasive ventilation
- 19 July 2013
- Published by Wiley in Muscle & Nerve
- Vol. 49 (4) , 545-550
Vascular endothelial growth factor and amyotrophic lateral sclerosis: The interplay with exercise and noninvasive ventilation
- 1 January 2013
- Published by INSTICC
- p. 54-59
A Method to Detect Keystrokes using Accelerometry to Quantify Typing Rate and Monitor Neurodegenerative Progression
- 1 January 2013
- Published by INSTICC
- p. 54-59
A Method to Detect Keystrokes using Accelerometry to Quantify Typing Rate and Monitor Neurodegenerative Progression
- 1 December 2012
- Published by Elsevier in Clinical Neurophysiology
- Vol. 123 (12) , 2454-2459
Phrenic nerve studies predict survival in amyotrophic lateral sclerosis
- 1 December 2012
- Published by Elsevier in Clinical Neurophysiology
- Vol. 123 (12) , 2454-2459
Phrenic nerve studies predict survival in amyotrophic lateral sclerosis
- 8 September 2012
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 14 (2) , 141-145
Primary lateral sclerosis: Predicting functional outcome
Our objective was to investigate functional outcome in primary lateral sclerosis (PLS). We followed a group of 24 patients with PLS. Clinical (ALSFRS), respiratory, and neurophysiological (electromyography and transcranial magnetic stimulation) evaluations were performed at entry and regularly over the follow-up period. The time taken for a greater than 10% decrease in ALSFRS compared to the first assessment was defined as the dichotomous outcome; prognostic factors were evaluated using the Cox proportional hazard model. Results demonstrated that the median age at symptom onset was 54 years (range 28−75 years). In 46% symptoms began in the lower limbs, in 21% in the upper limbs and in 33% in bulbar muscles. The median symptom duration at first visit was 3.1 years (range 0.9−11.7 years). At last follow-up the median disease duration was 9.9 years (range 4.2−17.6 years). The median follow-up time was 4.6 years (range 2.1−11 years). We excluded from final analysis three patients with positive family history. Older age at onset (p = 0.019) was related to more rapid functional impairment; gender, forced vital capacity, region of onset and neurophysiological changes did not predict outcome. In conclusion, age is the most critical prognostic factor for functional outcome in PLS.
- 8 September 2012
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 14 (2) , 141-145
Primary lateral sclerosis: Predicting functional outcome
Our objective was to investigate functional outcome in primary lateral sclerosis (PLS). We followed a group of 24 patients with PLS. Clinical (ALSFRS), respiratory, and neurophysiological (electromyography and transcranial magnetic stimulation) evaluations were performed at entry and regularly over the follow-up period. The time taken for a greater than 10% decrease in ALSFRS compared to the first assessment was defined as the dichotomous outcome; prognostic factors were evaluated using the Cox proportional hazard model. Results demonstrated that the median age at symptom onset was 54 years (range 28−75 years). In 46% symptoms began in the lower limbs, in 21% in the upper limbs and in 33% in bulbar muscles. The median symptom duration at first visit was 3.1 years (range 0.9−11.7 years). At last follow-up the median disease duration was 9.9 years (range 4.2−17.6 years). The median follow-up time was 4.6 years (range 2.1−11 years). We excluded from final analysis three patients with positive family history. Older age at onset (p = 0.019) was related to more rapid functional impairment; gender, forced vital capacity, region of onset and neurophysiological changes did not predict outcome. In conclusion, age is the most critical prognostic factor for functional outcome in PLS.
- 16 March 2012
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis
- Vol. 13 (6) , 550-554
What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis?
Percutaneous endoscopic gastrostomy (PEG) is a standard procedure for feeding dysphagic amyotrophic lateral sclerosis (ALS) patients. Nevertheless, the effect of prognostic factors influencing survival after PEG remains unclear. We aimed to evaluate the prognostic value of several clinical features on survival after PEG placement. This study investigated 151 patients with ALS, in whom a PEG was inserted over the last 16 years in our centre. Survival curves were determined by Kaplan-Meier and the analysis of potential prognostic factors was performed by a Cox regression model. The overall median survival was 32 months, longer in spinal-onset disease patients − 42 vs. 29 months in bulbar-onset patients (p < 0.001). Median survival after PEG placement was 7.5 months, similar in both bulbar- and spinal-onset patients, 7.9 vs. 7.1 months, respectively. Thirteen percent of patients died within one month after PEG placement; this short-term survival was influenced by low forced vital capacity (FVC < 50%). In a multivariate analysis, only older age at disease onset was independently associated with poor outcome after PEG placement. In conclusion, survival after PEG placement was similar in bulbar- and spinal-onset patients, suggesting that the latter were in a more advanced stage at the time of PEG placement. Low FVC was associated with higher risk of short-term mortality. Older age at disease onset was associated with poorer outcome in bulbar-onset patients. Younger bulbar-onset patients are those who benefited most from PEG.
- 16 March 2012
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis
- Vol. 13 (6) , 550-554
What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis?
Percutaneous endoscopic gastrostomy (PEG) is a standard procedure for feeding dysphagic amyotrophic lateral sclerosis (ALS) patients. Nevertheless, the effect of prognostic factors influencing survival after PEG remains unclear. We aimed to evaluate the prognostic value of several clinical features on survival after PEG placement. This study investigated 151 patients with ALS, in whom a PEG was inserted over the last 16 years in our centre. Survival curves were determined by Kaplan-Meier and the analysis of potential prognostic factors was performed by a Cox regression model. The overall median survival was 32 months, longer in spinal-onset disease patients − 42 vs. 29 months in bulbar-onset patients (p < 0.001). Median survival after PEG placement was 7.5 months, similar in both bulbar- and spinal-onset patients, 7.9 vs. 7.1 months, respectively. Thirteen percent of patients died within one month after PEG placement; this short-term survival was influenced by low forced vital capacity (FVC < 50%). In a multivariate analysis, only older age at disease onset was independently associated with poor outcome after PEG placement. In conclusion, survival after PEG placement was similar in bulbar- and spinal-onset patients, suggesting that the latter were in a more advanced stage at the time of PEG placement. Low FVC was associated with higher risk of short-term mortality. Older age at disease onset was associated with poorer outcome in bulbar-onset patients. Younger bulbar-onset patients are those who benefited most from PEG.
- 16 March 2012
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis
- Vol. 13 (6) , 533-537
Economic cost of home-telemonitoring care for BiPAP-assisted ALS individuals
Our objective was to measure direct (hospital and NHS) and indirect (patient/caregiver) costs of following up in-home compliance to non-invasive ventilation via wireless modem. We constructed a prospective controlled trial of 40 consecutive ALS home-ventilated patients, randomly assigned according to their residence area to G1 (nearby hospital, office-based follow-up) and G2 (outside hospital area, telemetry device-based follow-up). Total NHS direct cost encompassed costs related to outpatients’ visits (office and emergency room) and hospitalizations. Hospital direct costs included transportation to/from hospital, office visit per hour cost and equipment maintenance. Non-medical costs considered days of wages lost due to absenteeism. G1 included 20 patients aged 60 ± 10 years and G2 included 19 patients aged 62 ± 13 years. Results showed that no differences were found regarding clinical/demographic characteristics at admission. NHS costs showed a 55% reduction in average total costs with a statistically significant decrease of 81% in annual costs per patient in G2. Hospital costs were found to be significantly higher in G2 with regard to total costs (64% average increase) but not annual costs (7%). No statistical difference was found with regard to expenses from absenteeism. In conclusion, at the cost of an initial financial constraint to the hospital per year (non-significant), telemonitoring is cost-effective, representing major cost savings to the NHS in the order of 700 euros/patient/year.
- 16 March 2012
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis
- Vol. 13 (6) , 533-537
Economic cost of home-telemonitoring care for BiPAP-assisted ALS individuals
Our objective was to measure direct (hospital and NHS) and indirect (patient/caregiver) costs of following up in-home compliance to non-invasive ventilation via wireless modem. We constructed a prospective controlled trial of 40 consecutive ALS home-ventilated patients, randomly assigned according to their residence area to G1 (nearby hospital, office-based follow-up) and G2 (outside hospital area, telemetry device-based follow-up). Total NHS direct cost encompassed costs related to outpatients’ visits (office and emergency room) and hospitalizations. Hospital direct costs included transportation to/from hospital, office visit per hour cost and equipment maintenance. Non-medical costs considered days of wages lost due to absenteeism. G1 included 20 patients aged 60 ± 10 years and G2 included 19 patients aged 62 ± 13 years. Results showed that no differences were found regarding clinical/demographic characteristics at admission. NHS costs showed a 55% reduction in average total costs with a statistically significant decrease of 81% in annual costs per patient in G2. Hospital costs were found to be significantly higher in G2 with regard to total costs (64% average increase) but not annual costs (7%). No statistical difference was found with regard to expenses from absenteeism. In conclusion, at the cost of an initial financial constraint to the hospital per year (non-significant), telemonitoring is cost-effective, representing major cost savings to the NHS in the order of 700 euros/patient/year.
- 18 January 2012
- Published by Wiley in Muscle & Nerve
- Vol. 46 (3) , 341-345
Decreased heart rate variability predicts death in amyotrophic lateral sclerosis
Introduction: Some patients with amyotrophic lateral sclerosis (ALS) die suddenly despite normal nocturnal pulse oximetry (NPO), possibly due to dysautonomia.Methods: Forty‐four ALS patients without other medical conditions were studied. Heart rate variability was assessed through finger oximetry. The heart rate coefficient of variation (HR CV) was evaluated during nocturnal sleep. All patients were investigated at study entry (T1); 13 were tested 4 months later (T2), and 21 patients were investigated a further 24 months after entry (T3). Only recordings obtained from patients with normal NPO were accepted.Results: HR maximal, minimum, and median values remained stable. HR CV was similar between T1 and T2, but it decreased significantly at T3 (P < 0.01). Very low values were observed in 4 patients at T3 (HR CV <0.20), and 3 died suddenly within the following 2 months, despite normal NPO.Conclusions: Low HR CV is a potential marker of prognosis in ALS. Muscle Nerve 46: 341–345, 2012
- 18 January 2012
- Published by Wiley in Muscle & Nerve
- Vol. 46 (3) , 341-345
Decreased heart rate variability predicts death in amyotrophic lateral sclerosis
Introduction: Some patients with amyotrophic lateral sclerosis (ALS) die suddenly despite normal nocturnal pulse oximetry (NPO), possibly due to dysautonomia.Methods: Forty‐four ALS patients without other medical conditions were studied. Heart rate variability was assessed through finger oximetry. The heart rate coefficient of variation (HR CV) was evaluated during nocturnal sleep. All patients were investigated at study entry (T1); 13 were tested 4 months later (T2), and 21 patients were investigated a further 24 months after entry (T3). Only recordings obtained from patients with normal NPO were accepted.Results: HR maximal, minimum, and median values remained stable. HR CV was similar between T1 and T2, but it decreased significantly at T3 (P < 0.01). Very low values were observed in 4 patients at T3 (HR CV <0.20), and 3 died suddenly within the following 2 months, despite normal NPO.Conclusions: Low HR CV is a potential marker of prognosis in ALS. Muscle Nerve 46: 341–345, 2012